Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the teamsta severe htn study
The Journal of Clinical Hypertension, 04/27/2012Neutel JM et al.
Treatment of patients with substantially elevated blood pressure (SBP) with telmisartan/amlodipine (T/A) single–pill combinations (SPCs) resulted in high and significantly greater BP reductions and higher BP goal and response rates than the respective monotherapies. T/A SPCs were well tolerated.
This 8–week, randomized, double–blind, controlled study.
Compared efficacy and tolerability of telmisartan/amlodipine (T/A) single–pill combination (SPC) vs the respective monotherapies in 858 patients with severe hypertension (systolic/diastolic blood pressure [SBP/DBP] ≥180/95 mm Hg).
At 8 weeks, T/A provided significantly greater reductions from baseline in seated trough cuff SBP/DBP (–47.5 mm Hg/–18.7 mm Hg) vs T (P<.0001) or A (P=.0002) monotherapy; superior reductions were also evident at 1, 2, 4, and 6 weeks.
Blood pressure (BP) goal and response rates were consistently higher with T/A vs T or A.
T/A was well tolerated, with less frequent treatment–related adverse events vs A (12.6% vs 16.4%) and a numerically lower incidence of peripheral edema and treatment discontinuation.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.